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RESUMEN
Se describe un método espectrofotométrico sencillo, pre-
ciso y sensible para la determinación de clorhidrato de 
dopamina (DO·HCl) y levodopa (LD) tanto en formas puras 
como en sus formulaciones farmacéuticas comercialmen-
te disponibles. La idea principal del método se basa en 
hacer reaccionar una disolución de DO·HCl o LD a pH 12, 
utilizando un tampón universal, con 4-aminoantipirina (4-
AAP) para formar un producto de acoplamiento de color 
rosa con lmax = 475 (e = 1,46·104 l·mol-1·cm-1) o 454 
nm (1,05·104 l·mol-1·cm-1) para los compuestos DO·HCl 
y LD, respectivamente. Antes de aplicar la ley de Beer, se 
optimizan diferentes condiciones experimentales, tales 
como el tiempo, la temperatura, la secuencia de adición y 
el pH. El método de la razón molar revela que se obtiene 
un producto de acoplamiento 1:1 [ingrediente activo]:[4-
AAP]. Se examina si los excipientes habitualmente em-
pleados como aditivos en los preparados farmacéuticos 
interfieren en el procedimiento propuesto. Se realizan las 
curvas de calibración usando DO·HCl y LD estándares, 
con porcentajes de recuperación de 98,62 – 102,9% y 
97,40 – 101,5%, respectivamente. La ley de Beer es obe-
decida en el margen de concentraciones 37,90 – 170,6 y 
49,30 – 221,8 mg/L para DO·HCl y LD, respectivamente. 
Se evalúa la reproducibilidad y la precisión del método, 
obteniendo SD = 0,04-0,22 y 0,05-0,15, y RSD = 0,06-0,16 
y 0,02-0,10% para DO·HCl y LD, respectivamente. Estos 
resultados se comparan favorablemente con los de los 
métodos oficiales y publicados, tal y como apuntan los 
valores del test-t y del test F, indicando la posibilidad de 
aplicar este método espectrofotométrico en medidas de 
rutina.
Palabras clave: Espectrofotometría, método de las adi-
ciones estándar, clorhidrato de dopamina, levodopa, tam-
pón universal, 4-aminoantipirina, comprimidos, ampollas.
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SUMMARY
A Simple, accurate and sensitive spectrophotometric 
method for determining dopamine hydrochloride (DO·HCl) 
and levodopa (LD) in either pure forms or in their commer-
cially available pharmaceutical formularions is reported. 
The main idea of the method is based on reacting a solu-
tion of DO.HCl or LD at pH 12; using universal buffer, with 
4-aminoantipyrine (4-AAP) to form pink coloured coupling 
dye product with λmax = 475 (ε = 1.46x104 l·mol-1·cm-1) or 
454 nm (1.05x104 l·mol-1·cm-1) for DO·HCl and LD drugs, 
respectively. Before carrying out Beer’s law, different ex-
perimental conditions like time, temperature, sequence of 
addition and pH are optimized. The molar ratio method re-
vealed a 1:1 [active ingredient]:[4-AAP] coupling product. 
The common excipients used as additives in pharmaceuti-
cals are examined in our proposed procedure as interfering 
materials. The calibration curves were developed by using 
standard DO·HCl and LD with percent recovery of 98.62 
– 102.9 and 97.40 – 101.5%, respectively. Beer’s law was 
obeyed in the concentration range from 37.90 – 170.6 and 
49.30 – 221.8 mg/L of DO·HCl and LD, respectively. The 
reproducibility and accuracy of the method was checked 
by the values of SD = 0.04-0.22 and 0.05-0.15 and RSD 
= 0.06-0.16 and 0.02-0.10% for DO·HCl and LD, respec-
tively. The results compare favourably with those of official 
and reported methods as indicated by the t- and F-test 
values, indicating the possibility of applying this spectro-
photometric method in routine measurements.
Key words: Spectrophotometry, standard addi-
tion method, dopamine hydrochloride, levodopa, uni-
versal buffer, 4-aminoantipyrine, tablets, ampoules. 
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RESUM
Es descriu un mètode espectrofotomètric senzill, precís i 
sensible per a la determinació de clorhidrat de dopami-
na (DO·HCl) i levodopa (LD) tant en formes pures com en 
les seves formulacions farmacèutiques comercialment 
disponibles. La idea principal del mètode es basa en fer 
reaccionar una dissolució de DO·HCl o LD a pH 12, utilit-
zant un tampó universal, amb 4-aminoantipirina (4-AAP) 
per formar un producte d’acoblament de color rosa amb 
lmax = 475 (e = 1,46·104 l·mol-1·cm-1) o 454 nm (1,05·104 
l·mol-1·cm-1) per als compostos DO·HCl i LD, respecti-
vament. Abans d’aplicar la llei de Beer, s’optimitzen di-
ferents condicions experimentals, tals com el temps, la 
temperatura, la seqüència d’addició i el pH. El mètode de 
la raó molar revela que s’obté un producte d’acoblament 
1:1 [ingredient actiu]:[4-AAP]. S’examina si els excipients 
habitualment emprats com additius en els preparats far-
macèutics interfereixen en el procediment proposat. Es 
realitzen les corbes de calibratge emprant DO·HCl i LD 
estàndards, amb percentatges de recuperació de 98,62 – 
102,9% i 97,40 – 101,5%, respectivament. La llei de Beer 
és obeïda en el marge de concentracions 37,90 – 170,6 i 
49,30 – 221,8 mg/L per a DO·HCl i LD, respectivament. 
S’avalua la reproduïbilitat i la precisió del mètode, obtenint 
SD = 0,04-0,22 i 0,05-0,15, i RSD = 0,06-0,16 i 0,02-0,10% 
per a DO·HCl i LD, respectivament. Aquests resultats es 
comparen favorablement amb els dels mètodes oficials i 
publicats, tal i com apunten els valors del test-t i del test F, 
indicant la possibilitat d’aplicar aquest mètode espectro-
fotomètric en mesures de rutina.
Mots clau: Espectrofotometria, mètode de les addicions 
estàndard, clorhidrat de dopamina, levodopa, tampó uni-
versal, 4-aminoantipirina, comprimits, ampul·les.
I. INTRODUCTION
Dopamine and dopamine derivatives were a group of bio-
genic amines possessing a 3,4-dihydroxy substituted phe-
nyl ring (Figure 1).
DO; R: CH2 CH2 (NH2)
LD; R: CH(NH2)COOH
Fig. 1. Structural formulae of the investigated dopamines.
They considered as a type of hormones widely spread in 
animals and had also been detected in 44 plant families 
(1,2). They were participated in regulation of a wide variety 
of physiological functions and released in small amounts. 
Over the years, catecholamines and their metabolites re-
mained an important laboratory aid in the diagnosis of 
many physiological and psychiatric diseases. They also 
seemed to be a central pharmacophore and well probably 
existed in future drugs, especially in those developed for 
psychiatry disorders and neurological activity (3). They might 
act not only as transmitters from the neuro (endocrine) to 
the immune system but also as autocrine\paracrine me-
diators in immunocompetent cells and as transmitters be-
tween these cells and the nerves (4,5). It was not until the 
late 1950,s that dopamine was recognized as a mamalian 
neurotransmitter in its own right but the demonstration of 
its non-uniform distribution in the brain suggested that it 
might has a specific functional role for dopamine (6). It had 
therapeutic uses as a cardiostimulant for the treatment of 
acute circulatory insufficiency and hypotention and impor-
tant role in the pathogenesis or drug treatment of certain 
brain diseases e.g. Parkinson’s disease and Schizophrenia 
(7).
Administration of LD was a characteristic feature for Par-
kinson’s disease. It must be combined with certain amount 
from CD, which facilitate LD transport to the brain and con-
verted to dopamine in the basal ganglia (8). Several methods 
were applied on pharmaceutical preparations containing 
DO.HCl or LD depending on oxidation reaction (9,10). Deter-
mination of certain catechol derivatives likes pyrocatechol, 
DO.HCl and LD in either pure form or in its pharmaceuti-
cal formulation was suggested spectrophotometrically (11) 
by interaction of diazotized     p-nitroaniline with catechol 
derivatives in the presence of molybdate ions in acidic me-
dium, and indirect kinetic specrtophotometrically (12) with 
periodate in acidic medium. On the other hand, the inter-
action of DO.HCl with sodium salt of chloramine-T and 
traces of copper (II) ions in a phosphate buffer medium 
of pH = 7 (13) or trioxalatoferrate (III) complex (14) allowed 
formation of coloured products that can be detected spec-
trophotometrically in pharmaceutical ampoules.
Chromatographic methods (15-17) were utilized or the de-
termination of catecholamines in pharmaceutical and bio-
logical fluids. Flow injection analysis (FIA) system using 
tubular electrode was used in the determination of DO in 
pharmaceutical preparations (18,19). Also, determination of 
levodopa and dopamine in pharmaceutical preparations 
using spectrophotometric methods were carried out (20-23).
The theory of active ingredient reaction with reagents illus-
trated as follows: different colorimetric methods described 
for phenol determination (24, 25) were based on the reaction 
between phenols and 4-AAP to form antipyrine dyes where 
4-AAP was found to be the most sensitive, fastest and pre-
cise colourimetric reagents. 4-AAP reacted with phenolic 
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 Fig 2. Coupling reaction between phenol and 4-AAP.
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type compounds according to the reaction show in Fig. 2. 
The reaction product might be any colour from red to pur-
ple depends on the phenolic type compounds involved. 
In continuation to our interest in microdetermination of 
these drugs under study (26), the aim of the present work 
is to describe the development of simple, sensitive and 
rapid spectrophotometric method for the determination 
of DO.HCl and LD depending upon the formation of their 
coupled products with 4-AAP at pH = 12. Different expe-
rimental conditions are carefully studied before applying 
Beer’s law. The method was applied for determining 
DO.HCl and LD in pure form and pharmaceutical forms 
(tablets and ampoules) and the results obtained are com-
pared well with those obtained by the official method.
II. ExPERIMENTAL
Apparatus
Absorption spectra measurements were recorded using 
Melton Roy Spectronic 601 and automated Perkin-Elmer 
Model Lambda 20 UV-Vis spectrophotometer in the wave-
length range from 200 to 900 nm. The pH measurements 
were done using a Titrino Metrohm 716 DMS, connected 
to Metrohm stirrer. This instrument has a combined glass 
and reference electrodes used for pH measurements. For 
selecting accurate volumes, the calibrated micro-pipette 
(BRAND) of disposable plastic tips was used in the range 
100 - 1000 µL. The water used was always de-ionized ob-
tained from the instrument model Altra Clear SG-Wasser 
aufbereitung und Regenerierststion GmbH. HPLC was 
carried out using Perkin-Elmer instrument with binary LC 
pumb (250), C18 analytical column (250x4.60 mm) and uv-
vis spectrophotometric detectoer (LC 290).
Materials
All reagents were of the analytical grade. Dopamine hy-
drochloride (DO.HCl) supplied from Sigma, while levodopa 
(LD), carbidopa (CD) and 4-aminoantipyrine (4-AAP) were 
purchased from Fluka Chemie AG. Sodium hydroxide was 
supplied from BDH. Glacial acetic, boric and phosphoric 
acids (90%) were purchased from Aldrich. Dopamine hy-
drochloride present in pharmaceutical preparations as 
dopamine Fresenius and Dopamine Pierre Fabre concen-
trate ampoules for infusion (200 mg/5 mL), where they 
were supplied from Fresenius Kabi, Deutschland GmbH, 
D61346 Bad Homburg v.d.H. and Pierre Fabre Medica-
ment Production, Boulonge, respectively. Levocar tablets 
labeled 250 mg levodopa and 25 mg carbidopa were sup-
plied from Alpha Chem. Advanced Pharmaceutical Indus-
tries Co. (ACAPI).
Reagents
10-2 M stock solutions of DO.HCl and LD were prepared 
in de-ionized water. The stock and dilute solutions were 
stored in dark bottles under cold condition (4 °C) in refrig-
erator. 10-2 – 10-3 M solutions of 4-AAP were prepared in 
100 mL de-ionized water. All the required dilutions from 
reagents were prepared from stock one. A mixture of 0.04 
M phosphoric, boric and acetic acids was titrated with 0.2 
N NaOH to adjust the desired pH into 12 using pH-meter. 
0.1 M Solution of interfering materials (glucose, ascorbic 
acid, catechol, phenol, pyrogallol, resorcinol, and hydro-
quinone) were prepared by dissolving the accurate cal-
culated weight in 25 mL de-ionized water. 10-2 – 10-3 M 
solutions of the interfering materials were prepared by ac-
curate dilution from the stock one.
LD-CD synthetic mixture was prepared to have 10:1 [LD]/
[CD] ratio as that in Levocare drug where 0.1999 g and 
0.0182 g of LD and CD, respectively, were dissolved in 100 
mL de-ionized water. The concentration of each drug in 
the synthetic mixture becomes [LD] = 1.014x10-2 M and 
[CD] = 8x10-4 M.
Procedure
An aliquot containing 37.90-170.7 or 49.30-221.8 ppm 
of DO.HCl or LD, respectively, was transferred to 10 mL 
measuring flask, followed by adding 10-2 M   4-AAP. The 
pH was adjusted using universal buffer of pH = 12. The 
total volume was completed up to 10 mL. The mixtures 
were shacked well and allowed to stand at 30 ± 3 °C for 
30 and 35 minutes, the pH was rechecked and the absorb-
ance was measured at 475 and 454 nm for DO.HCl and 
LD, respectively, against de-ionized water as a blank. The 
calibration curves were obtained applying the same proce-
dure using standard solutions of active ingredient.
Certain volume from dopamine ampoule (200 mg\5 mL) was 
diluted in 250 mL volumetric measuring flask to prepare 0.1 
M solution. Then incubated in cold, dark bottles and away 
from oxygen air to prevent oxidation or decomposition 
Twenty tablets of Levocare were accurately weighed and 
the average weight of one tablet was calculated. The tab-
lets were crushed well to a fine powder. A portion of the 
powder equivalents to 250 mg LD-25 mg CD was dis-
solved in 100 mL de-ionized water. The resulting solutions 
were shacked well, filtered through a Whatmann No. 1 filter 
paper and washed with de-ionized water. The filtrate and 
washings were collected in 100 mL measuring flask then 
diluted to the volume with the same solvent. Aliquots of 
solutions of analyte were transferred to 10 mL measuring 
flask and quantitated applying our proposed procedure.
0.15 or 0.1 mL of DO.HCl ampoule or LD-CD tablet solu-
tion was mixed with serial known concentrations of ac-
tive ingredients DO.HCl (1.1x10-4- 6.5x10-4 mmole) or LD 
(3.75x10-4- 8.75x10-4 mmole) solutions, respectively. The 
mixtures were mixed with 0.01 M 4-AAP and the proce-
dure was completed as mentioned before.
RESULTS AND DISCUSSION
Determination of DO.HCl and LD using 4-AAP at pH =12
Optimum conditions affecting the reaction of DO.HCl and 
LD with 4-AAP are studied carefully.
By adding 4-AAP to DO.HCl and LD solutions in de-ionized 
water, colourless solutions were observed with λmax = 278 
nm (  = 5.77x104 and 5.52x104 L mol-1cm-1) for DO.HCl and 
LD, respectively. The addition of universal buffer of different 
pH values (Table 1); from 2 to 12, to 4-AAP with DO.HCl 
or LD is studied and complete absorption spectra of these 
solutions from 200 to 900 nm are recorded.  Colourless 
solutions were observed from pH 2 to 11 for both active 
ingredients with 4-AAP with λmax = 260 (  = 5.02x104 - 5.25 
x104 and 4.66x104- 4.89x104 L mol-1cm-1 for DO.HCl and LD, 
respectively), 279 (  = 5.6x104 – 6.03 x104 and 5.23x104- 
5.6x104 L mol-1cm-1 for DO.HCl and LD, respectively) and 
282  nm  (  =  6.28x104  –  7.1x104  and   5.88x104 -  5.92 x104  
L mol-1cm-1 for DO.HCl and LD, respectively). At pH = 12, a 
new pink coloured product is formed between DO.HCl or 
LD with 4-AAP with λmax = 475 (  = 1.46 x104 L mol-1cm-1) or 
454 nm (  = 1.05 x104 L mol-1cm-1), respectively (Table 1). 
Applying the molar ratio method, it is found that DO.HCl or 
LD interacts with 4-AAP to form 1:1 [4-AAP]: [active ingre-
dient] product under alkaline condition of pH = 12. 
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The effect of time on the reaction of DO.HCl or LD with 
4-AAP is studied in the presence of universal buffer of pH 
= 12 and at λmax = 475 or 454 nm, respectively. This Factor 
was studied at different time intervals to select the suitable 
time needed for microdetermination of DO.HCl and LD as 
shown in Fig. (3). During the first 30 minutes, the absorb-
ance increases with increase of time. Approximately in the 
period 32 – 60 and 35 – 45 minutes for DO.HCl and LD, 
respectively, the absorbance is nearly constant and after 
that the time slowly increases. Therefore, the most suit-
able time for microdetermination of DO.HCl and LD using 
4-AAP and universal buffer of pH = 12 is 32 and 35 min-
utes, respectively.
The temperature is one of the factors that highly affect the 
formation of coloured products. Figure (4) shows the effect 
of temperature on the coupling products between active 
ingredient (DO.HCl or LD) and 4-AAP in the temperature 
range from 15 to 60 0C. It was observed that by increas-
ing the temperature from 15 to 30 0C and 15 0C to 35 0C 
in case of DO.HCl and LD with 4-AAP at pH = 12, respec-
tively, the absorbance increases. In between 30-40 0C for 
DO.HCl and 35- 50 0C for LD, the absorbance is approxi-
mately constant. Above these temperatures, the lighting in 
colour of the coupling products is observed and the ab-
sorbances slowly decrease. Therefore, It is concluded that 
the most suitable temperature for microdetermination of 
DO.HCl and LD with 4-AAP using universal buffer of pH = 
12 are 30 ± 2 and 40 ± 2 0C, respectively (Figure (4).
Under the optimum conditions, a correlation was ob-
tained between absorbance (A) and the concentration (C) 
over the range 27.90-170.6 and 49.30-221.8 µg mL-1 of 
DO.HCl and LD, respectively (Fig. (5)). The apparent molar 
absorptivity, Sandell sensitivity, standard deviation (SD), 
and coefficient of variation (CV) for each active ingredient 
are tabulated in Table (2). The apparent molar absorpitiv-
ity (ε) of the resulting coloured products are found to be 
3.375x104 and 2.434x104 L. mol-1.cm-1, whereas Sandell 
sensitivities are 3.9x10-3 and 2.9x10-3 g cm-2 for DO.HCl 
and LD, respectively. The correlation coefficient is found 
to be 0.999, while the SD is 0.04-0.22 and 0.05-0.10 for 
DO.HCl and LD, respectively. The low values of CV and SD 
indicate the high accuracy, precision, and reproducibility 
of the proposed method to determine the cited drugs. 
Interference
This factor is studied depending on the nature of our active 
ingredient where it may be secreted naturally in body or 
present as pharmaceutical preparation. This study is con-
centrated on the additives, which may commonly present 
in the pharmaceutical preparations or natural secreted flu-
ids in urine. The common tolerances, which examined with 
our active ingredients (DO.HCl and LD) using 4-AAP and 
universal buffer of pH 12 reagents, are glucose, acetone, 
urea, ascorbic acid, catechol, phenol, pyrogallol, resorcinol 
and hydroquinone. From Tables (3), it is observed that, the 
presence of tolerances such as glucose, acetone, urea, py-
rogallol or hydroquinone with DO.HCl and glucose with LD 
as ten folds, have completely no effect on the microdeter-
mination of LD as seen from the percent recoveries (99.40 
– 100.0%). The presence of ascorbic acid in the media 
has a great effect on the quantitativeness of the reaction. 
As the ascorbic acid concentration decreases to have the 
same concentration of active ingredient, the microdetermi-
nation of DO.HCl or LD can be carried out approximately 
without interference (percent recovery = 102 – 107 %). The 
presence of phenol or catechol with DO.HCl or phenol, 
catechol, pyrogallol, resorcinol or hydroquinone with LD as 
ten folds, they highly affect the micreodetermination of the 
active ingredients giving high % error. By decreasing the 
concentration of phenol or hydroquinone to be the same 
as DO.HCl or LD the percent recovery raised up to 97 or 
106 %, respectively.   
Finally, we can concluded that, quantitative determination 
of DO.HCl can be carried out in the presence of glucose, 
acetone, urea, hydroquinone, pyrogallol and low concentra-
tion of ascorbic acid and phenol. In case of LD, the quanti-
tative determination can be applied in presence of glucose 
and low concentrations of ascorbic acid and phenol.
Determination of LD in LD-CD synthetic mixtures 
In order to prove the applicability to determine LD in some 
pharmaceutical forms like Levocare, synthetic mixtures 
containing LD and CD were prepared and analyzed for 
LD determination using our proposed procedure and the 
data obtained are listed in Table (3). In these mixtures, the 
percent recovery of LD is ranged from 101.4 to 102.4 %. 
These data reflect the high sensitivity of this procedure for 
microdetermination of LD in presence of CD. 
Application
Determination of LD in pharmaceutical forms
LD used as neurotrasmitter in the management of neural 
disorders such as those associated to Parkinson’s disease 
(27). LD formulation associated with CD, which enhances 
the action of LD by inhibiting its decarboxylation and 
lengthening its therapeutic effect as a result.       
Quantitative determination of LD in pharmaceutical prepa-
ration (tablets), which has collected from the commercial 
markets, is carried out using the proposed spectrophoto-
metric method and official HPLC method (28).
From HPLC method, the retention time was found to be = 
2.12 min for LD and 4.10 min for CD. Then the proposed 
and HPLC methods are applied on the drug matrix which 
prepared before (see experimental part). The results ob-
tained in Table (5) show that the percentage recovery is 
found to be very close to those obtained by the official 
method with percent error of 1.10-3.70% that can be ne-
glected where it present in the international acceptable 
range of error for pharmaceuticals determination (29). In or-
der to check the confidence and correlation between the 
suggested procedure and the official method for microde-
termination of LD, it is better to calculate the t- and F-tests 
(Table 5). The calculated t-test at the 95% confidence level 
is 0.91-1.02, while, the calculated F values are 4.0-5.85. 
It is obvious from these results that the t and F values did 
not exceed the theoretical values. The results obtained 
are considered to be of high accuracy and the methods 
can be successfully applied for the microdetermination of 
LD in row materials and in the commercial pharmaceutical 
preparations which contain LD.
Determination of DO.HCl in pharmaceutical prepara-
tions (ampoules) 
The DO.HCl ampoule is used as an injection treatment 
with patients who suffering from ischemic heart disease. 
Determining DO.HCl in dosage form, manufactured in the 
local companies, is the mean idea of this paper in order 
to test the accuracy and presicion of the proposed proce-
dure. The concentration of the drugs in the dosage forms 
is calculated from the appropriate calibration graph. Before 
carrying out microdetermination, the absorption spectrum 
of the drugs is carried out. It is found that, there is no shift 
in λmax due to the presence of other constituents present in 
the dosage forms.
Table (5) shows the results obtained for the determination 
of DO.HCl in dosage forms coming from two different com-
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panies and labeling mg per ampoule. Two different am-
poule concentrations of DO.HCl; 76.61 and 153.23 mg/L; 
were determined applying the proposed procedure under 
selected optimum conditions of pH, time, temperature, ra-
tio and wavelength and using official HPLC technique (30). 
The data listed in Table (5) show the precision and repro-
ducibility of the results with a percent error of 1.80–5.0% 
with SD = 0.11 - 0.22. The low values of SD indicate the 
successful application of our proposed method for the de-
termination of DO.HCl in pharmaceutical preparations. 
The results are compared with those obtained applying the 
official method (28). The DO.HCl solution, using HPLC, is 
found to have a retention time of = 2.93 min. The results 
obtained are compared statistically by F- and t-tests with 
those obtained by official method on the sample of the 
same batch. The F- and t-test values obtained at the 95% 
confidence level are 4.0-6.84 and 0.85 – 0.17, respectively. 
It is clear from Table (5) that, the calculated F- and t-test 
values does not exceed the theoretical tabulated values 
indicating that there is no significant difference between 
accuracy of the proposed and the official methods.
The final recommendation is that the proposed procedure 
can be applied for microdetermination of DO.HCl in phar-
maceutical preparations. The percent error can be neglect-
ed where the ampoule contain not less than 95.0% and 
not more than 105.0 % of the labeled amount of dopamine 
hydrochloride (29, 31).  
quantitative determination of pharmaceutical prepara-
tions using standard addition method (SAM)
The standard addition method (SAM) is applied to support 
the validity of application of our proposed procedure for 
microdetermination of DO.HCl and LD in their pharmaceu-
tical preparations and to minimize the effect of any matrix 
interference’s in quantitative determination of active ingre-
dient in the commercial available drugs.  
The SAM is applied on pharmaceutical preparations con-
taining LD and DO.HCl as active ingredients. The extrapola-
tion of the line of calibration curve intersected with the x-
axis at 49.00 and 29.00-29.50 mg\L with percent error of 
0.6 and 1.0% and SD = 0.22 and 1.07 for LD and DO.HCl, 
respectively (as shown in Table (6)). This gives the real con-
centration of active ingredient (LD and DO.HCl) present in 
the pharmaceutical preparations. The high values of the per-
cent recovery reflect the high efficiency of applying standard 
addition method for microdetermination of the drugs under 
investigation in their pharmaceutical preparations.
CONCLUSION
The proposed method for DO.HCl and LD estimation is 
advantageous over many reported methods. This may be 
attributed to their sensitivity, rapidity, noninterference with 
other ingredients usually present in pharmaceutical prep-
arations, precision and good agreement with the official 
method. Hence this method can be used for the routine 
analysis.
BIBLIOGRAPHY
1. Juan, C.; Yan-Ping, S. and Jing-Yan L., J. Chromatog-
raphy A, 2003, 1003 (1-2), 127-132.
2. Jan S.; Grzegorz W.; Oliver F.; Andreas W. and Lothar 
W., Phytochemistry, 2001, 59 (2), 315-320.
3. Loutala, P., “Catechol O-methyltransferase: Glucuro-
nidation of Inhibitors and Methylation of Substrates”. 
University of Helsink, Finland, 2000.
4. Marino, F.; Cosentino, M.; Bombelli, R.; Ferrari, M.; 
Lecchini, S. and Frigo, G., Exp. Hematol., 1999, 27: 
489-495.
5. Musso, N. R.; Brenci, S.; Setti, M.; Indiveri, F.; Lotti, 
G., J. Clin. Endocrinol. Metab., 1996, 81, 3553-3557.
6. Rodriguez, M. C.; Obeso, J. A. and Olanow, C. W., 
Ann. Neurol., 1998, 44, S 175.
7. Professor Philip G. Strange, http:/www.tocris. com/ 
dopamine. htm, published October 2000. 
8. Kaakkola, S.; Tuomainen, P.; Wurtman, R. J. and Man-
nisto, P. T., J. Neural. Transm.; Parkinsons Dis. De-
mentia Sect., 1992, 4(2), 143.
9. Puttaswamy.; Jagadeesh, R.V. and Vaz, Nirmala., 
Central European Journal of Chemistry., 2005, 3 (2), 
326-346. 
10. Coello, J.; Maspoch, S. and Villegas, N., Talanta, 
2000, 53(3), 627-637. 
11. Nagaraja, P.; Vasantha, R.A. and Sunitha, K.R., J. 
Pharm. Biomed. Analysis, 2001, 25:3-4, 417-424. 
12. Afkhami, A. and Khatami, H.A., J. Analytical. Chem., 
2003, 58 (2), 135-138.
13. Nagaraja, P.; Murthy, K. C. Srinivasa; Yathirajan, H. S. 
and Mohan, B. M., Indian J. Pharm. Sci., 1998, 60(2), 
99-101.
14. Nour El-Dien, F. A. and Rashwan, N. A. A., Egypt. J. 
Chem., 1995, 38(2), 125-39.
15. Zhang, Y.X.; Zhang, Z.J. and Yang, F. Chinese  J. 
Chem. 2008, 26(3), 489-494.
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20. Önal, A.; Caglar, S. Chem. and Pharmac. Bull. 2007, 
55(4), 629-631.
21. Abdulrahman, L.K.; Al-Abachi, A.M. and Al-Qaissy, 
M.H. Analytica Chimica Acta, 2005, 538(1-2), 331-
335. 
22. Shaikh, S.M.T.; Manjunatha, D.H.; Harikrishna, K.; 
Ramesh, K.C. and Kumar, R.S. J. Anal. Chem. 2008, 
63(7), 637-642.
23. Nagaralli, B.S.; Seetharamappa, J.; Melwanki, 
M.B.; Ramesh, K.C. and Keshavayya, J. J. AOAC In-
ternat., 2002, 85(6), 1288-1292. 
24. Chen, Y.; Wang, S. and Zhou, T. Anal. Lett., 1998, 31, 
1233.
25. Uslu, B. and Ozkan, S.  Anal. Lett., 2002, 35, 303. 
26. Nour El-Dien, F.A.; Zayed, M.A.; Mohamed, Gehad G. 
and El-Nahas, Reham G. J. Biomed. Biotech., 2005, 
1, 1-9.
27. Bravo, E.L. Endcor Rev., 1994, 15, 356-68.
28. Sinclair, D.; Shenkin, A. and Lorimer, A.R. Ann. Clin. 
Biochem., 1991, 28, 417-9.
29. British Pharmacopiea, 1998,1150-1151.
30. HPLC, applications (Macherey-NAGel), K. Gobler, 
Dissertation, 1980, Erlangen-Numberg, Germany.
31. U.S. Pharmacopeia, National Formulory, 1995.
AfinidAd LXVi, 541, Mayo-Junio 2009248
λ max
(nm)
Є (L mol-1 cm-1)
DO.HCl
Є (L mol-1 cm-1)
LD
De-ionized water 278 5.77x104 5.52x104
pH = 2 260 5.25x104 4.89x104
3 260 5.04x104 4.87x104
4 260 5.02x104 5.23x104
5 279 5.6x104 5.60x104
6 279 6.03x104 5.92x104
7 179 6.28x104 5.88x104
8 279 6.37x104 5.88x104
9 279 6.54x104 5.84x104
10 279 6.49x104 5.84x104
11 282 7.10x104 5.88x104
12 285 8.31x104 7.37x104
475 1.46x104 ------------
454 ------------------ 1.05x104
Table (1): Effect of different 
pH on molar absorbitivity (Є) of 
DO.HCl and LD with 4-AAP using 
universal buffer (pH = 2-12).
Parameters DO.HCl LD
λmax (nm) 475 454
T (°C) 30 ± 2 40 ± 2
t, min 32 35
Detection range (mg/L) 37.90 – 170.6 49.30 – 221.8
Correlation coefficient 0.999 0.999
ε (L.mol-1cm-1) 3.375x104 2.434x104
SD 0.04-0.22 0.05-0.15
CV (%) 0.06-0.16 0.02-0.10
Sandell Sensitivity (mg cm-2) 3.9x10-3 2.9x10-3
Table (2): Different analyti-
cal parameters for the de-
termination of DO.HCl and 
LD using 4-AAP reagent and 
universal buffer (pH = 12).
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Table (3): Effect of different 
tolerances on the determination 
of  DO.HCl and LD using 4-AAP 
and universal buffer of pH = 12.
Table (4): Determination of LD 
in the LD-CD synthetic mix-
ture using 4-AAP and univer-
sal buffer. [4-AAP] = 3x10-3 
M, [LD] = 2.44x10-3 M, [CD] 
= 2.4x10-4 M, pH = 12, t = 35 
min, T = 38 0C, λmax = 454 nm.
Tolerant
DO.HCl LD
Fold
A % recovery Fold A % recovery
Drug ----- 0.333 100.0 ----- 0.414 100.0
Glucose 10 0.333 100.0 101
0.416
0414
100.5
100.0
Acetone 10 0.331 99.40 ----- ----- -----
Ascorbic acid
10
1
0.5
0.005
0.341
0.331
-------
102.4
99.40
10
1
0.5
0.017
0.447
0.418
4.10
107.9
101.1
Urea
10
1
0.5
0.327
0.330
0.331
98.23
99.10
99.40
------- ------ ------
Catechol 100.5
0.766
0.522
230.0
156.7
10
1
0.66
0.547
159.4
132.1
Phenol
10
1
0.5
0.310
0.323
0.328
93.1
97.00
98.50
10
1
0.5
0 .455
0.433
0.412
109.9
104.6
99.50
Pyrogallol 101
0.328
0.306
98.50
91.90
10
1
0.643
0.551
155.3
133.1
Resorcinol 101
0.040
0.095
-------
-------
10
1
0.328
0.352
79.20
85.00
Hydroquinone 101
0.329
0.331
98.80
99.40
10
1
0.5
0.306
0.442
0.395
73.90
106.7
95.40
[LD] = 96.23 mg\L [LD] = 192.5 mg/L
A (mg/L) found % recovery A (mg/L) found % recovery
0.300 96.75 100.5 0.539 196.33 102
0.304 98.42 102.3 0.544 197.42 102.5
0.300 96.75 100.5 0.541 197.16 102.4
0.305 98.83 102.7 0.543 198.0 102.8
0.303 98.00 101.8 0.547 197.66 102.7 
Amean
0.302
97.58 101.4
Amean
0.541
197.52 102.46
SD 0.29 SD 0.36
CV % 0.29 CV % 0.18
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Table (5): Determination of DO.HCl and LD in pharmaceutical preparations using 4-AAP reagent and universal buffer (pH = 12).
Table (6): Determination of 
DO.HCl and LD in pharma-
ceutical preparations using 
standard addition method.
Fig. (3): Effect of time on the 
absorbance of (a) DO.HCI 
and (b) LD with 4-AAP and 
universal buffer of pH = 12
Drug
Name of
preparation
[Drug],
Taken 
(mg/l)
Proposed method Officila method
t-test* F-test *
Found 
(mg/l)
% 
recovery
SD
Found 
(mg/l)
% 
recovery
SD
DO.HCl
- Dopamine Fresenius
- Dopamine Pie-
rre Fabre
76.61
153.2
76.61
153.2
76.62
153.7
79.28
151.2
100.4
100.3
103.4
98.60
0.11
0.13
0.12
0.16
77.23
152.4
78.30
154.9
100.8
99.17
102.2
101.1
0.28
0.26
0.22
0.25
0.85
1.40
1.43
1.70
6.48
4.00
3.36
2.44
LD
- Alpha Chem. Ad-
vanced Pharmaceutical 
Industries Co. (ACAPI). 
98.60
197.2
97.00
191.9
98.20
97.30
0.13
0.11
98.20
188.8
99.60
98.40
0.26
0.26
0.91
1.02
4.00
5.58
F*- test: are the values for V as degree of freedom for variation at 95% confidence level = 6.39.
  t*-test: are the values for V as degree of freedom for 95% confidence level = 2.779.
Drug
Name of
preparation
[Drug],
Taken (mg/l)
Proposed method
Found 
(mg/l)
% recovery SD
DO.HCl
- Dopamine Fresenius
- Dopamine Pierre Fabre
28.70
28.70
29.00
29.50
101.0
105.0
0.15
0.12
LD
- Alpha Chem. Advanced 
Pharmaceutical Indus-
tries Co. (ACAPI). 
49.30 49.00 99.40 0.22
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Fig. (5). Calibration curves for 
the determination of (a) DO.HCl 
(pH = 12, t = 32 min, T = 30 °C 
and λ = 475 nm) and (b) LD (pH 
= 12, t = 38 min, T = 38 °C and λ 
= 454 nm) using 4-AAP reagent. 
Fig. (4): Effect of temperature 
on the reaction of (a) DO.HCI 
and (b) LD with 4-AAP using 
universal buffer of pH = 12
